Smallpox Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Smallpox Treatment Market Trends and Insights

Government Stockpiling and Medical-Countermeasure Procurement

Stockpile refresh contracts remained the largest revenue driver for the smallpox treatment market. In March 2025, SIGA Technologies received a USD 26 million order for IV TPOXX under its BARDA 19C contract, following a USD 113 million oral TPOXX order in July 2024. In June 2026, Emergent BioSolutions received a USD 52.7 million contract modification for ACAM2000 vaccine, ancillaries, and diluent replacement lots. The National Academies stated that anthrax and smallpox capacity sustainment was expected to account for nearly two-thirds of Strategic National Stockpile procurement spending during FY2022 through FY2026.^{[1]National Academies of Sciences, Engineering, and Medicine, “Future State of Smallpox Medical Countermeasures, Chapter 2, State of Smallpox Medical Countermeasures Readiness,” National Academies, nationalacademies.org.} These requirements favored suppliers that already met Animal Rule, quality, and stockpile qualification standards.

Orthopoxvirus Preparedness After Mpox Outbreaks

The 2022 multi-country mpox outbreak changed how many governments assessed orthopoxvirus preparedness. Governments increasingly positioned smallpox medical countermeasures as assets with applications beyond a narrow bioterrorism scenario. Bavarian Nordic reported DKK 3,105 million (approximately USD 450 million) in Public Preparedness revenue in 2025, including government demand for its MVA-BN vaccine platform. Bavarian Nordic’s April 2024 EU strategic reserve contract for MVA-BN was valued at EUR 65 million (approximately USD 70 million) and helped establish a coordinated procurement route for member states. Research on vaccine development and stockpiling also highlighted the shift toward more coordinated preparedness arrangements in Europe. South Korea’s National Vaccine Stockpiling Mid- to Long-Term Plan for 2024 to 2028 indicated that preparedness was becoming part of longer-term national planning. This broader buyer base supported the smallpox treatment market even without an active smallpox event.

Reduced Population Immunity After Routine Smallpox Vaccination Ended

Routine smallpox vaccination ended after eradication in 1980, leaving people born after that year without baseline vaccination-derived orthopoxvirus immunity. This increased the population that authorities would need to protect during a reintroduction event. The National Academies identified waning immunity as a reason for the United States to diversify its smallpox medical countermeasures and improve vaccine and therapeutic options. As a result, some preparedness discussions moved stockpile planning beyond narrow ring-vaccination assumptions. A larger susceptible population increased the value of products that authorities could deploy quickly outside specialist treatment settings. Recognition of other orthopoxviruses, including Alaskapox and vaccinia-like viruses, further supported ongoing readiness planning. Although this demand was precautionary, it provided the smallpox treatment market with a longer-term public health rationale.

Animal Rule Pathway for Approval Without Human Efficacy Trials

The FDA Animal Rule enabled approvals when human efficacy trials were not ethical or feasible. This pathway played a central role in the approval of TPOXX and Tembexa for smallpox. It allowed developers to use animal efficacy evidence, along with other required data, for products intended for an eradicated disease. The process shortened the route from research funding to a stockpile-ready product compared with a conventional clinical program. It also allowed governments to consider procurement before developers could generate human Phase 3 efficacy evidence. The EMA used related exceptional-circumstances provisions for tecovirimat. This regulatory framework gave established developers an advantage because building suitable animal models, manufacturing capacity, and government relationships took several years.

Eradicated Disease and Minimal Routine Clinical Demand

The variola virus does not circulate in any human population, making all purchases precautionary. Governments fund preparedness for a severe but uncertain event, which can strain budgets as other public health priorities compete for funding. The WHO Smallpox Vaccine Emergency Stockpile supports countries that do not maintain independent reserves and also reflects uneven global coverage. With no routine clinical demand, the smallpox treatment market depends on sustained policy commitment and government willingness to maintain inventory.

Limited Human Efficacy Evidence for Approved Therapeutics

The EMA removed the mpox indication for tecovirimat in March 2026 after clinical trial findings did not support the indication. However, it retained a positive benefit-to-risk balance for smallpox, cowpox, and vaccinia complications. Smallpox approvals remain based on the Animal Rule because conventional human efficacy trials are not possible. This creates a policy risk if governments seek stronger real-world evidence before renewing contracts, increasing the importance of resistance monitoring, post-authorization evidence, complementary mechanisms, and clear deployment data.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Antiviral Drugs and Vaccines Serve Complementary Stockpile Roles

Antiviral drugs held a 60.34% share in 2025, led by tecovirimat in national stockpiles across the United States, Canada, Europe, and Japan. The segment benefits from demand for treatment after exposure. The FDA approved TPOXX for oral smallpox treatment in 2018 and approved an intravenous formulation in 2022 for patients unable to take capsules. Public health authorities also hold brincidofovir as a second-line option under the Animal Rule, while cidofovir remains relevant in institutional protocols despite intravenous administration and renal toxicity concerns.

Vaccines are projected to be the fastest-growing product group, registering an 8.82% CAGR through 2031. In March 2025, the FDA approved a freeze-dried JYNNEOS formulation, improving its suitability for long-term storage. BARDA exercised USD 143.6 million in options under Bavarian Nordic’s existing 10-year supply contract, with deliveries planned for 2026. ACAM2000 remains part of the United States Strategic National Stockpile and received expanded FDA approval for mpox in 2024, while Japan’s LC16m8 and Moderna’s mRNA-1769 candidate support future supply diversity.

By Disease Type: Variola Major Concentrates Market Economics and R&D Priority

Variola Major held 68.36% of the smallpox treatment market size in 2025 and is also forecast to register the fastest 8.23% CAGR through 2031. Preparedness plans focus on this form because it historically caused the highest disease burden and presents the clearest biodefense concern. Its historical case fatality rate ranged from 15% to 35%, compared with below 1% for Variola Minor. Animal model studies use related orthopoxvirus surrogates, keeping development and procurement focused on the more severe threat scenario.

Variola Minor, hemorrhagic smallpox, malignant smallpox, and modified smallpox make up the remainder of this segmentation. Hemorrhagic and malignant forms historically had very high fatality rates, but their rarity limited their role in volume modeling. Modified smallpox may present atypical clinical features in partially immune people, including vaccinated military personnel and healthcare workers. A large event in a low-immunity population could increase demand for intravenous antivirals, supportive care products, and multiple therapeutic formats.

By Route of Administration: Oral Products Gain Ground While Parenteral Products Remain Central

Parenteral products held a 72.36% share in 2025, reflecting the institutional deployment model for vaccines and intravenous antivirals. Healthcare providers administer vaccines through subcutaneous or intradermal routes, while intravenous tecovirimat and cidofovir remain necessary for patients unable to take oral therapy. The share reflects stockpile composition more than patient preference. Hospitals and public health agencies continue to rely on parenteral products for severe cases, vaccine campaigns, and emergency treatment protocols.

Oral products are forecast to grow at a 9.35% CAGR through 2031. Oral tecovirimat is suitable for mass-dispensing scenarios where intravenous capacity would be constrained. SIGA’s BARDA 19C contract includes a supplemental new drug application planned within 12 months for oral tecovirimat as smallpox post-exposure prophylaxis. If approved, that indication would extend oral use beyond treatment and give governments more flexible deployment options without replacing the need for parenteral medicines.

By End User: Public Health Agencies Lead While Hospitals and Clinics Expand

Public health agencies held a 42.32% share in 2025. They manage procurement, stockpile oversight, and distribution in most major purchasing countries. In the United States, ASPR and CDC structures manage these roles, while HERA and rescEU support coordinated preparedness in Europe. Japan’s Ministry of Health, Labour and Welfare plays a comparable role in national planning, and military and defense agencies remain important buyers through separate preparedness programs.

Hospitals and clinics are forecast to register the highest end-user CAGR at 8.54% through 2031. Governments are increasingly considering pre-positioned hospital reserves that can be activated without waiting for central logistics. This shift reflects lessons from COVID-19, when centralized stockpiles could not always meet immediate local needs. Hospitals also provide clinical capacity for severe cases and intravenous administration, while ambulatory care centers and homecare settings may become more relevant for oral post-exposure prophylaxis.

By Distribution Channel: Government Stockpiles Dominate While Hospital Pharmacies Grow

Government and strategic stockpiles held a 74.68% share in 2025. This channel dominates because government institutions act as the primary buyers and prepare these products for public emergencies. The U.S. Strategic National Stockpile, EU rescEU reserve, Japan’s national stockpile, Canadian preparedness reserves, and the WHO emergency stockpile provide the core demand base. Commercial distribution remains limited under normal conditions, as public procurement cycles determine product availability.

Hospital pharmacies are expected to be the fastest-growing channel, registering an 8.16% CAGR through 2031. Their expansion follows the broader move toward decentralized readiness. They can support severe case treatment and controlled dispensing of oral antivirals, while specialty pharmacies remain relevant for compassionate use and expanded-access programs. Retail pharmacies would matter mainly in a mass-dispensing event, and hospital pharmacy growth changes where inventory is held without displacing government purchasing.

Geography Analysis

North America held a 43.21% share in 2025. The United States supported regional demand through the Strategic National Stockpile, BARDA development funding, and Project BioShield procurement authority. Multi-year purchase agreements for vaccines and antivirals created a predictable demand base for established suppliers. Canada formalized multi-year medical countermeasure arrangements, while Mexico remained a smaller market aligned with Pan American Health Organization guidance.

Asia-Pacific is forecast to grow at a CAGR of 8.76% from 2026 to 2031. Japan approved TEPOXX and used LC16m8 within its bioterrorism response framework. SIGA received a USD 13 million oral TPOXX order from an Asia-Pacific customer in January 2026 under a multi-year agreement. South Korea’s 2024 to 2028 vaccine stockpiling plan indicated a shift from event-based purchasing to longer-term preparedness.

Europe developed a coordinated reserve model through rescEU and HERA while retaining national programs in Germany, France, and the United Kingdom. Bavarian Nordic secured MVA-BN orders for the EU strategic reserve, supporting regional vaccine capacity. France confirmed in May 2026 that tecovirimat remained authorized for smallpox, cowpox, and vaccinia complications after the mpox indication was withdrawn. The Middle East and Africa remained at an earlier stage in formal stockpile development, while Brazil and Argentina built capacity in line with Pan American Health Organization frameworks.